Import from '@/components/mdx'

Rezdiffra (Resmetirom) and Diphenhydramine: Drug Interaction Guide for Women

What Is Resmetirom and Why Do Women Take It?

Resmetirom (brand name Rezdiffra) is the first FDA-approved pharmacologic therapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (F2-F3). The FDA granted approval in March 2024 for adults with noncirrhotic MASH paired with a reduced-calorie diet and increased physical activity.

MASH is not a disease that affects men and women equally. Women face a distinct hormonal overlay: estrogen is hepatoprotective during the reproductive years, and the loss of estrogen after menopause accelerates hepatic fat accumulation and fibrosis progression. Studies published in Hepatology estimate that postmenopausal women have up to a 3.5-fold higher risk of advanced MASH fibrosis compared with premenopausal women of similar metabolic profiles. Women with PCOS carry an even earlier risk; PCOS is independently associated with NAFLD/MASH in up to 55% of affected women, driven by hyperinsulinemia and androgen excess.

How Resmetirom Works

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. THR-beta receptors are concentrated in the liver, where thyroid hormone signaling governs fatty acid oxidation, lipogenesis, and bile acid metabolism. By selectively activating hepatic THR-beta, resmetirom reduces intrahepatic triglyceride content without the cardiac and bone effects associated with systemic thyroid excess.

In the phase 3 MAESTRO-NASH trial involving 966 patients, resmetirom 100 mg achieved MASH resolution without fibrosis worsening in 25.9% of participants versus 14.2% on placebo, and fibrosis improvement of at least one stage in 25.9% versus 14.2% (p < 0.001 for both).

Life-Stage Considerations for Women on Resmetirom

Reproductive years and PCOS. Women with PCOS who develop MASH may be candidates for resmetirom, but insulin-sensitizing therapy (metformin, inositol) and weight management remain first-line. Resmetirom's effect on ovarian function has not been studied in humans.

Perimenopause. This is the window where MASH risk accelerates and where diphenhydramine use is most common, because many perimenopausal women self-medicate for sleep disruption with over-the-counter sleep aids that contain diphenhydramine. The co-prescription risk discussed in this article is therefore most clinically relevant for women aged 45-55.

Post-menopause. Women who are postmenopausal and on resmetirom for established MASH may also be taking antihistamines for allergic rhinitis, insomnia, or skin conditions. Dose caution applies in this group because hepatic metabolism can be slower with age.

Understanding the Pharmacokinetic Interaction

The interaction between resmetirom and diphenhydramine is not a single mechanism. It has two distinct pharmacokinetic layers and one pharmacodynamic layer.

CYP2C8: The Shared Metabolic Pathway

Resmetirom is primarily metabolized by CYP2C8 and CYP3A4, as stated in the FDA-approved Rezdiffra prescribing information. Diphenhydramine is also a CYP2C8 substrate, and at higher or repeated doses it exerts mild inhibitory pressure on CYP2C8.

When two CYP2C8 substrates compete for the same enzyme:

• Metabolic clearance of the primary substrate (resmetirom) may slow.
• Plasma resmetirom concentrations may rise beyond the expected range.
• Dose-dependent adverse effects of resmetirom, including nausea, diarrhea, and hepatic enzyme elevations, could be more pronounced.

The magnitude of this interaction depends on dose and duration of diphenhydramine use. A single 25 mg diphenhydramine tablet taken once is unlikely to produce a clinically detectable change in resmetirom exposure. Daily use of 50 mg (two standard tablets) taken repeatedly is a different scenario.

P-glycoprotein Efflux

Resmetirom is also a substrate of P-glycoprotein (P-gp). Diphenhydramine has weak P-gp inhibitory activity. This secondary transporter interaction is unlikely to be clinically significant at standard antihistamine doses, but it reinforces why daily or high-dose diphenhydramine use deserves specific attention rather than dismissal.

Sex-Specific Pharmacokinetics: Why This Matters More for Women

Women metabolize many CYP2C8 substrates differently from men. Sex differences in CYP enzyme activity mean that women often show higher peak plasma concentrations of CYP2C8 substrates compared with men at the same weight-adjusted dose. This is partly because women tend to have lower hepatic blood flow per unit of liver mass, and partly due to estrogen's effects on gene expression of certain CYP isoforms.

For resmetirom specifically, the MAESTRO-NASH trial did not publish sex-stratified pharmacokinetic data in its primary paper. This is a real evidence gap. What the prescribing information does note is that body weight is used to set dose (80 mg for body weight <100 kg; 100 mg for body weight ≥100 kg), and that no dedicated sex-based dose adjustment is recommended by the FDA label. Women deserve to know that sex-specific PK data are extrapolated from general population modeling rather than directly studied.

Understanding the Pharmacodynamic Interaction

Beyond the metabolic pathway competition, diphenhydramine adds a pharmacodynamic burden that resmetirom itself does not carry in isolation.

CNS Sedation

Diphenhydramine crosses the blood-brain barrier readily and antagonizes central H1 receptors, producing sedation, impaired reaction time, and cognitive slowing. Resmetirom does not have direct CNS activity, but its adverse event profile from MAESTRO-NASH includes dizziness and fatigue in a small proportion of users. Combining a sedating antihistamine with any medication that lists dizziness as an adverse effect creates an additive burden.

A 2021 meta-analysis in Sleep Medicine Reviews found that diphenhydramine produces clinically significant next-day cognitive impairment in adults over age 50 at standard OTC doses. This is directly relevant for the perimenopausal and postmenopausal woman who is already contending with brain fog from hormonal fluctuation.

Anticholinergic Load

Diphenhydramine carries substantial anticholinergic burden. The American Geriatrics Society Beers Criteria explicitly flags diphenhydramine as a drug to avoid in adults over 65 due to anticholinergic toxicity risk including constipation, urinary retention, and delirium. While MASH itself is not a disease of older adults exclusively, women who are postmenopausal and on resmetirom fall squarely into the population where anticholinergic load matters clinically.

Clinical Severity Rating and What the DDI Databases Say

Standard drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the resmetirom-diphenhydramine interaction as moderate based on the CYP2C8 substrate overlap. There is no published clinical pharmacokinetic study of this specific pair. The rating is mechanism-based and extrapolated from known CYP2C8 interaction data, not from a dedicated crossover trial.

What this means practically:

• The combination is not contraindicated.
• It is not listed as a "do not use together" interaction in the Rezdiffra prescribing information.
• The FDA label for resmetirom does warn about use of strong CYP2C8 inhibitors (such as gemfibrozil, which can raise resmetirom AUC by 150% or more), placing diphenhydramine in a much lower-risk category by comparison.

A practical decision framework for women on resmetirom who want to use diphenhydramine:

| Scenario | Risk Level | Recommendation | |---|---|---| | Single 25 mg dose, once | Low | Acceptable; monitor for excess sedation | | 25-50 mg nightly for 3-7 days (allergy season) | Low-to-moderate | Discuss with prescriber; consider loratadine instead | | 50 mg nightly, ongoing (sleep aid) | Moderate | Switch to evidence-based sleep intervention; avoid routine use | | 75-100 mg in combination with other CNS agents | Moderate-to-high | Do not use; escalate to prescriber |

Safer Alternatives to Diphenhydramine for Women on Resmetirom

The good news: you have options that carry less interaction risk and less anticholinergic burden.

For Allergies

Loratadine (Claritin) and cetirizine (Zyrtec) are second-generation antihistamines. Loratadine is minimally metabolized by CYP2C8 and has no meaningful CNS penetration. Cetirizine is primarily renally excreted with minimal hepatic CYP involvement. Either is a substantially safer antihistamine choice for a woman taking resmetirom.

Fexofenadine (Allegra) is also a reasonable option. It is a P-gp substrate but does not inhibit CYP2C8 at therapeutic doses.

For Perimenopausal Sleep Disruption

Sleep disruption in perimenopause is driven largely by vasomotor symptoms and hypothalamic-pituitary dysregulation. Diphenhydramine does not address the underlying hormonal cause and loses effectiveness within four to six nights due to rapid tolerance.

Evidence-based options that carry no CYP2C8 interaction with resmetirom include:

• Cognitive behavioral therapy for insomnia (CBT-I): considered first-line by the American Academy of Sleep Medicine for chronic insomnia in adults.
• Low-dose doxepin 3-6 mg (prescription only): approved for sleep maintenance insomnia and has minimal CYP2C8 activity.
• Melatonin receptor agonists (ramelteon): low interaction potential with resmetirom.
• Hormone therapy: if vasomotor symptoms are driving sleep disruption, NAMS 2022 position statement supports systemic hormone therapy for symptomatic women under age 60 or within 10 years of menopause onset who do not have contraindications.

Pregnancy, Lactation, and Contraception

This section is required reading for any woman of reproductive age taking resmetirom.

Pregnancy

Resmetirom is contraindicated in pregnancy. The Rezdiffra prescribing information carries an embryo-fetal toxicity warning based on animal reproductive studies showing adverse developmental effects at exposures below the human therapeutic dose. No adequate and well-controlled studies exist in pregnant women, and none should be expected given the embryo-fetal toxicity signal in animals.

If you are pregnant or planning to become pregnant, do not take resmetirom. Discontinue it before attempting conception and discuss timing with your prescriber.

Contraception Requirement

The FDA label requires that women of reproductive potential use effective contraception while taking resmetirom and for at least two weeks after the final dose. This is not optional guidance. It mirrors the contraception requirement seen with other hepatotoxic or teratogenic agents. Given that MASH is common in women with PCOS who may also have irregular cycles and reduced fertility awareness, this point deserves explicit discussion at every prescribing encounter.

Lactation

It is not known whether resmetirom is present in human breast milk, whether it affects milk production, or whether it has any effect on the breastfed infant. The FDA label advises against breastfeeding during resmetirom treatment and for two weeks after the final dose because of the potential for serious adverse reactions in the nursing infant.

Diphenhydramine, separately, transfers into breast milk in small amounts. The LactMed database maintained by NIH rates diphenhydramine as possibly problematic during lactation due to infant sedation and the theoretical risk of apnea in neonates. A breastfeeding woman should not be on resmetirom, so the combined lactation risk is hypothetical, but it underscores that neither drug is safe during breastfeeding.

Who Is (and Is Not) a Candidate for Resmetirom

Women Who May Benefit Most

• Postmenopausal women with biopsy-confirmed MASH (F2-F3 fibrosis) who have not achieved adequate response to lifestyle modification alone.
• Premenopausal women with PCOS-associated MASH and moderate-to-advanced fibrosis, with appropriate contraception in place.
• Women with metabolic syndrome phenotype (central adiposity, dyslipidemia, insulin resistance) who meet the MAESTRO-NASH enrollment criteria.

Women for Whom Resmetirom Is Not Appropriate

• Pregnant women or those planning pregnancy: absolute contraindication.
• Women with cirrhosis: the MAESTRO-NASH trial enrolled F2-F3 patients; cirrhosis (F4) was an exclusion criterion.
• Women with decompensated liver disease: resmetirom has not been studied in this population.
• Women with uncontrolled hypothyroidism: because resmetirom acts on thyroid hormone receptors, thyroid status should be optimized before initiation. The prescribing information notes that resmetirom can reduce TSH levels, which requires monitoring.

Monitoring and What to Watch For When Both Drugs Are Used

If you and your prescriber determine that short-term diphenhydramine use is acceptable alongside resmetirom, watch for these signals:

Symptoms to Report Promptly

• Unusual or excessive daytime sleepiness.
• Dizziness severe enough to affect balance or driving.
• Nausea or diarrhea beyond your baseline on resmetirom (may indicate elevated drug exposure).
• Yellowing of skin or eyes, dark urine, or right upper quadrant pain (hepatic adverse effects of resmetirom, which occur in a minority of patients but require prompt evaluation).

Lab Monitoring

The Rezdiffra prescribing information recommends monitoring liver biochemistry (ALT, AST, total bilirubin) at baseline and periodically during treatment. Adding a hepatotoxic drug, even at low risk, is a reason to ensure your next scheduled labs are not delayed.

Thyroid function tests (TSH, free T4) should also be checked at baseline and at regular intervals, because resmetirom suppresses TSH as a pharmacodynamic effect.

Timing Strategy If Diphenhydramine Is Taken

Resmetirom is taken once daily. If short-term diphenhydramine use cannot be avoided, separating the dosing timing by six to eight hours will not eliminate the metabolic interaction (which is sustained over 24 hours due to half-life), but it may reduce the peak CNS sedation overlap. Resmetirom's half-life is approximately five to eight hours, meaning it should be taken consistently at the same time each day.

Talking to Your Prescriber: What to Say

Many women do not mention OTC antihistamine use to their prescribers because they assume it is harmless. Diphenhydramine is purchased at checkout with no prescription and widely perceived as low-risk. With resmetirom, that assumption needs revisiting.

A 2019 survey published in JAMA Internal Medicine found that 38% of adults taking prescription medications did not disclose all OTC drug use to their physician. Among women, the most common undisclosed OTC categories included sleep aids and allergy medications, which are precisely the categories where diphenhydramine sits.

Before your next prescribing appointment, prepare a complete list of every OTC medication, supplement, and sleep aid you take. Specifically mention:

• Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs, Tylenol PM).
• Any herbal sleep products (valerian, melatonin, chamomile in high-dose extract form).
• Any antifungals (fluconazole is a significant CYP2C8 inhibitor and interacts more strongly with resmetirom than diphenhydramine does).
• Gemfibrozil: the Rezdiffra label specifically contraindicates concomitant use with gemfibrozil due to a large increase in resmetirom AUC.

Your prescriber can then advise based on your full picture, not a partial medication list.

The Evidence Gap Women Should Know About

Clinical trials for resmetirom, including MAESTRO-NASH, enrolled a mixed-sex population. In MAESTRO-NASH, approximately 52% of participants were female, which is relatively equitable by historical standards. Sex-stratified efficacy and safety data have not been published in the primary report, meaning that whether women achieve the same histologic response rate as men, at the same dose, remains an open question.

Drug interaction studies for resmetirom followed standard FDA DDI guidance and tested gemfibrozil and rifampicin (a CYP inducer). A specific diphenhydramine-resmetirom pharmacokinetic crossover study has not been conducted or published. The moderate interaction rating is therefore mechanism-based extrapolation.

This does not mean the interaction is trivial. It means the precise magnitude of the exposure change in a 52-year-old perimenopausal woman taking 80 mg resmetirom and 50 mg diphenhydramine nightly for two weeks is not known from clinical data. Until that data exists, caution is appropriate.

The responsible clinical position: avoid routine diphenhydramine use while on resmetirom, and if short-term use is genuinely necessary, use the lowest effective dose for the shortest duration and tell your prescriber.